Trade AstraZeneca ^AZN

AstraZeneca Announces $1.5 Billion Efficiency Drive to Fuel Drug Pipeline Growth, ETPharma

AstraZeneca (NYSE:AZN) Share Price Crosses Above 200 Day Moving Average - Time to Sell?

AstraZeneca (LON:AZN) Share Price Crosses Above Two Hundred Day Moving Average - Time to Sell?

89,287 AstraZeneca Plc $AZN Shares Sold by Apollon Wealth Management LLC

AstraZeneca (LON:AZN) Given "Buy" Rating at Jefferies Financial Group - Daily Political

Q3 earnings round-up: AstraZeneca, AbbVie, Kenvue

Healthcare Stocks Trade Higher: CDNA Gains 20%, REGN Adds 12%, PROF Climbs 10%, AZN Advances 7%

AstraZeneca (NYSE: AZN) Core EPS climbs 14% and full-year guidance holds - Zolmax

AstraZeneca Stocks Rise 7.65% With $2 Billion Restructuring Cost Ceiling

AstraZeneca (LON:AZN) Stock Jumps 7% - What's Next?

Best Manufacturing Stocks To Research - October 30th - Zolmax

Learn Why The Bull Case For AstraZeneca Stock Could Change Following Earnings Beat

AstraZeneca (LON:AZN) Stock Rating Reaffirmed as Buy by Jefferies Financial Group - Markets Daily

Clinics: Biontech, Genmab ADCs hit PFS for breast, ovarian cancer

AstraZeneca (NYSE:AZN) Shares Gap Up - Here's What Happened

AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth

AstraZeneca launches overhaul to cut costs by £1.1bn a year

AstraZeneca profit jumps 23% on cancer drugs as it unveils major savings plan

AstraZeneca Q3 Earnings Call Highlights - Daily Political

AstraZeneca (LON:AZN) Earns "Buy" Rating from Jefferies Financial Group - Stock Observer

AstraZeneca CEO Sees Over $20B Potential From 2027 Drug Trial Readouts - AZN Stock Eyes Breakout After Q3 Earnings Beat

AstraZeneca CFO Aradhana Sarin on Q3 results, oncology portfolio and drug pipeline outlook

Market Open: NatWest Flat Profit, AstraZeneca Revenue Rise

AstraZeneca Q3 Profit Rises; Pipeline Delivers 12 Positive Phase 3 Readouts; Stock Up

AstraZeneca (AZN) Q3 2026 Earnings Results & Report

AstraZeneca Plc $AZN Stake Trimmed by Park Avenue Securities LLC

AstraZeneca Q3 Profit Rises; Reconfirms FY26 Revenue, Core EPS Guidance At CER

AstraZeneca Q3 revenue up 7% as cancer drugs offset Farxiga drop

AstraZeneca Posts Revenue, Profit Growth on Strong Cancer-Drug Sales | Morningstar

AstraZeneca kicks off $1.5 billion savings drive to invest in drug pipeline

Daiichi Sankyo H1 Profit Rises 16% As Cancer Drugs Lift Revenue; Backs FY26 Outlook

Lab Rats series: A Bengaluru startup's bid to drug the undruggable

How Investors May Respond To AstraZeneca (LSE:AZN) EU Breast Cancer Approval

AI CRM Adoption Could Be A Key Catalyst For Veeva Systems Stock (VEEV)

Global HER2 Targeted Therapies Market Report 2026 | Capitalize on 8.6% CAGR as Pfizer, Roche, AstraZeneca, and Daiichi Sankyo Advance ADCs and Precision Oncology

AstraZeneca Bulls Back Drug Pipeline to Boost Laggard Stock

AstraZeneca PLC (LON:AZN) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

An agentic AI system enhances clinical detection of immune-related adverse events in a multi-phase validation study

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing | Morningstar

Mark-Paul Gosselaar on 'Paralysis' of Watching Family Members Navigate Cancer and How It Inspired His Advocacy (Exclusive)

Micron Biomedical Appoints Anand Subramony, Ph.D., as Executive Vice President, Global Product Development and Combination Product Commercialization

AstraZeneca (AZN) Projected to Announce Earnings on Friday

43,432 AstraZeneca Plc $AZN Shares Purchased by Generali Asset Management SPA SGR

AstraZeneca Plc $AZN Stock: Generali Asset Management SPA SGR Grows Holdings - Markets Daily

Cardiff Names Alland Interim Medical Chief Ahead Of Planned Phase 3 Cancer Trial

Erste Group Bank Lowers Earnings Estimates for AstraZeneca - Daily Political

AstraZeneca may start work on cancer vaccines, CEO says

AstraZeneca May Enter Cancer Vaccine Development, CEO Says

AstraZeneca offers compelling risk-reward into 2027 pipeline readouts, says JPMorgan

AstraZeneca, Daiichi Sankyo's Enhertu Wins First EU Approval In Early Breast Cancer Setting

AstraZeneca Names Onco360 National Speciality Pharmacy Partner For Zegfrovy

Valley National Advisers Inc. Sells 12,839 Shares of Astrazeneca Plc $AZN

AstraZeneca, Daiichi Sankyo Drug Gets EU Nod in Early-Stage Breast Cancer | Morningstar

AstraZeneca Projects $80 Bln In Total Revenue By 2030, Sustained Growth Beyond

Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

Ctrl, Alt, Cure: AI codes next miracle drug

AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update

Is AstraZeneca's Pipeline Fuel Enough to Spark a Post-Earnings Breakout on Oct. 30?

AstraZeneca's Sone-Ve Cuts Death Risk By 42% In Advanced Gastric Cancer Trial; Stock Up

AstraZeneca's Tagrisso Combo Achieves Significant Survival Benefit In Lung Cancer Trial; Stock Up

Cancer Innovation Must Not Become Corporate Spoils -By Fransiscus Nanga Roka

Dow Jones Top Company Headlines at 3 AM ET: Roche Targets Emerging Oncology Market With New Lung-Cancer Drug | AstraZeneca ... | Morningstar

UK Stock Market Today: FTSE 100 Futures Dip As Firm PMIs Meet Rate Worries

AstraZeneca's Sone-ve Drug Shows Promising Survival Rates in Advanced Stomach Cancer Trials, ETPharma

EMEA Morning Briefing: Central Bank Decisions in Focus This Week | Morningstar

Dow Jones Top Company Headlines at 1 AM ET: AstraZeneca Readies New Portfolio of Targeted Cancer Therapies | Musk ... | Morningstar

Dow Jones Top Company Headlines at 11 PM ET: AstraZeneca Readies New Portfolio of Targeted Cancer Therapies | Musk ... | Morningstar

Notorious Vancouver escort charged with robbery in Ontario | Watch News Videos Online

Amgen announces Phase 3 results of Imdelltra with AstraZeneca's Imfinzi

AstraZeneca announces results from the SAFFRON Phase III trial of Tagrisso

AstraZeneca announces results from DeLLphi-305 trial of IMFINZI

AstraZeneca announces results from VOLGA Phase III trial of IMFINZI

DZ BANK AG Reaffirms Their Buy Rating on arGEN X (0QW0)

New Amgen drug combination shows survival gains in lung cancer trial

Amgen-AstraZeneca drug combination cut risk of death in small cell lung cancer by 58%

Amgen Reports Combo Cuts Lung Cancer Death Risk 58%

8,009 Shares of Astrazeneca Plc $AZN Purchased by Sowell Financial Services LLC

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial

Head-To-Head Contrast: Lifecore Biomedical (NASDAQ:LFCR) vs. Astrazeneca (NYSE:AZN) - Markets Daily

Contrasting Astrazeneca (NYSE:AZN) and Lifecore Biomedical (NASDAQ:LFCR) - Zolmax

Cancer Patents Must Protect Discovery Without Capturing Competition -By Fransiscus Nanga Roka

UK Stock Market Today: FTSE 100 Futures Edge Up On Sticky Inflation Test

Astrazeneca (AZN) Expected to Announce Quarterly Earnings on Friday

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial

Astrazeneca Pharma India Ltd Stock Price: Astrazeneca Phar Share Price Today | India Infoline

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

China-made cancer drug to go on sale in US after Americans travel to buy it

Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026

AstraZeneca's Ultomiris Gets FDA Accelerated Approval As First C5 Inhibitor For IgAN

AstraZeneca Adds New Indication for Ultomiris Drug in Rare Kidney Disease | Morningstar

AstraZeneca says Ultomiris approved to reduce proteinuria

Small Cell Lung Cancer Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and Route of Administration Trends | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca | ABNewswire

Ovarian Cancer Pipeline 2026: Emerging Drugs, Regulatory Milestones, and Strategic Moves by Leading Players | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact | ABNewswire

Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial

Boeing Stock Forecast 2026–2030: Can a Record $745 Billion Backlog Reverse BA’s 11% Earnings Sell-Off?

CoreWeave Stock Forecast 2026–2030: Can CRWV Recover From the AI Debt Sell-Off?

Pound to Rand Forecast: Can GBP/ZAR Break Above 22?

Nebius Stock Price Prediction 2026–2030: Can AI Cloud Growth Justify the Cost?

Eli Lilly Stock Forecast 2026–2030: Can LLY Break Above $1,300 After Its 7% Five-Session Rally?

Is Oracle a Good Buy Right Now? Growth, Valuation and Long-Term Risks

Best Stock CFD Broker in 2026: 9 Platforms Compared

Is SpaceX a Good Stock to Buy in 2026?

Best Gold Stock to Buy Now: 6 Gold Stocks to Watch in 2026

Advanced CFD Trading Tools Review: Which Tools Can Improve Your Trading Decisions?

Amazon Q3 Earnings: AWS Growth Hits 39.3% as AI Spending Weighs on Cash Flow

Intel Stock Crashes 18% as Weak Q4 Forecast Overshadows 78% AI Server Growth

Gold Price Today: Gold Slips Below $4,000 Despite Treasury Rally

Bitcoin Price Falls Below $80,000 as Binance Reports $6.3 Billion Security Incident

Alphabet Stock Falls 12% as Search Slowdown and AI Spending Unsettle Investors

Apple Earnings Preview: Can iPhone Growth and the Duo Foldable Justify AAPL’s Valuation?

Gold Price Today: XAU/USD Holds Near $4,050 as Fed Pause Leaves Rate Risks in Focus

Alphabet Stock Falls About 10% After Earnings Miss as AI Spending Weighs on Cash Flow